CXCR4 and melanoma: Moreover, treatment with CXCR4 antagonists has demonstrated robust inhibition of murine B16-OVA melanoma growth (20), and enhanced survival has been reported in multiple mouse models when a CXCR4 antagonist is combined with a checkpoint inhibitor (19, 20).